

Reference:	FOI.17843.25
Subject:	Oncology medicines
Date of Request:	17 July 2025

Requested:

1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
 - Atezolizumab (Tecentriq)
 - Durvalumab (Imfinzi)
 - Nivolumab (Opdivo)
 - Pembrolizumab (Keytruda)
 - Chemotherapy
 - Radiotherapy
 - Chemotherapy AND Radiotherapy
 - Osimertinib
2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?
3. How many patients has your Trust treated in total in the past 3 months for
 - Stage 2 Non-Small Cell Lung Cancer
 - Stage 3 Non-Small Cell Lung Cancer
4. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
 - Atezolizumab
 - Pembrolizumab monotherapy
 - Pembrolizumab with chemotherapy
 - Nivolumab
 - Osimertinib
 - Durvalumab
 - Chemotherapy
 - Radiotherapy
 - Chemotherapy and Radiotherapy
5. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with:
 - Chemotherapy
 - Radiotherapy
 - Chemotherapy + Radiotherapy
6. How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Durvalumab

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for questions 3, 5 and 6, as it is estimated that the cost of answering your request would exceed the “appropriate limit” as stated in the Freedom of Information Act 2000 (Appropriate Limit and Fees) Regulations 2004. The “appropriate limit” represents the estimated cost of one person spending 18 hours (or 2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The UHB is unable to easily identify the stage of a patient’s cancer diagnosis as this information is not recorded centrally. Identifying how many stage 2 and stage 3 Non-Small Cell Lung Cancer (NSCLC) patients have been treated within the last three months, as requested in question 3, would require a manual trawl of all NSCLC cancer patient records, to identify which patients have been diagnosed as stage 2 or 3, and in turn cross-reference with pharmacy and treatment records to identify any treatments received within the specified date range.

Similarly, in order to identify information for questions 5 and 6, the UHB would need to undertake a manual trawl of all NSCLC cancer patient records as explained above to identify the staging of each patient. It would then need to cross-reference these records to identify those patients who have had surgery and/ or then further review records to identify the treatments listed in your request within the specified date range.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000 (FoIA), which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the appropriate limit.

However, under Section 16 of the FoIA, we are required as a public authority, to provide advice and assistance so far as it is reasonable to individuals who have made a request under the FoIA, which can include assisting a requester to further refine their request.

In relation to the treatment by cancer stage data requested under questions 3, 5 and 6, the UHB is unable to suggest any refinements to the information request, as a manual trawl would still be required to identify patients before reviewing any treatment received.

Aside from the Section 12 exemption detailed above, the UHB provides the accessible information it holds for your other questions, below.

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested for questions 1 and 4, due to the low number of NSCLC patients (less than 5), recorded on the ChemoCare system as having received the treatments listed during the time period requested, as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA.

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

Further to this, the UHB regrets to inform you that it does not hold the information requested for Radiotherapy. The UHB's patients that require Radiotherapy treatment are seen and treated in Singleton Hospital, within Swansea Bay University Health Board (SBUHB).

Therefore, we recommend that you redirect this part of your request to the Freedom of Information Team at SBUHB, who may be able to help you further. The contact details are as follows:

FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.

1. The UHB has applied a section 40 exemption to your request.
2. In considering your request, the UHB has assumed that Stage II Melanoma relates to Adjuvant Melanoma patients.

Therefore, the UHB can inform you that sixteen (16) Adjuvant Melanoma patients were recorded on the ChemoCare system, as having been treated with Pembrolizumab between 1 April and 30 June 2025

3. The UHB has applied a section 12 exemption to your request.
4. The UHB has applied a section 40 exemption to your request.
5. & 6. The UHB has applied a section 12 exemption to your requests.